Background The effect of anlotinib combined with epidermal growth factor receptor TKIs
(EGFR-TKIs) in patients with advanced non-small cell lung cancer (NSCLC) with acquired …

Primary bronchial lung cancer, referred to as lung cancer, is one of the malignant tumors
with high morbidity and mortality in China and other countries in the world, accounting for …

Background Anlotinib and apatinib, both vascular endothelial growth factor receptor-tyrosine
kinase inhibitors (VEGFR-TKIs), are clinically established in the treatment of advanced non …

Objective. To compare the clinical efficacy and long‐term survival between anlotinib
monotherapy and anlotinib plus docetaxel in patients with lung carcinoma. Methods …

Background Anlotinib is an oral tyrosine kinase inhibitor targeting vascular endothelial
growth factor receptor, fibroblast growth factor receptor, platelet‐derived growth factor …

Methods Eligible patients were treatment-naive, stage IIIB/IV NSCLC patients without
EGFR/ALK/ROS1 mutations. Participants were given sintilimab (200mg IV day1 q3w) and …

Background Elderly pts have limited therapy strategies compared to the younger pts.
Anlotinib is a novel multi Tyrosine Kinase Inhibitor targeting the VEGFR, FGFR, PDGFR and …

The vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are involved in
activation of angiogenesis during tumor progression. Therefore, blockade of VEGF or …

Background Anlotinib hydrochloride is a novel TKI targeting the VEGFR, FGFR, PDGFR and
c-Kit. ALTER0303 trial (NCT02388919), phase III study has demonstrated that Anlotinib …

Background Anlotinib is a novel tyrosine kinase inhibitor with promising anti-tumor activity in
patients with advanced non-small cell lung cancer (NSCLC). The aim of this study was to …